Receptor activator NF κB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis

被引:232
|
作者
Crotti, T
Smith, MD
Hirsch, R
Soukoulis, S
Weedon, H
Capone, M
Ahern, MJ
Haynes, D
机构
[1] Univ Adelaide, Dept Pathol, Adelaide, SA, Australia
[2] Flinders Med Ctr, Dept Med, Adelaide, SA, Australia
[3] Univ Adelaide, Sch Dent, Adelaide, SA, Australia
[4] Repatriat Gen Hosp, Rheumatol Res Unit, Adelaide, SA, Australia
[5] Flinders Univ S Australia, Dept Med, Adelaide, SA 5001, Australia
关键词
bone; periodontitis; receptor activator of nuclear factor kappa B ligand; osteoprotegerin; immunohistochemistry; T lymphocytes;
D O I
10.1034/j.1600-0765.2003.00615.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objectives and background: This study investigated the expression of key mediators that regulate differentiation of osteoclasts, receptor activator of nuclear factor KB ligand (RANKL), and its natural inhibitor, osteoprotegerin (OPG), in periodonitis. We aimed to compare the levels of the RANKL and OPG in the granulomatous tissue adjacent to areas of alveolar bone loss from patients with periodontitis to that present in tissue from patients without periodontitis. In addition, we aimed to determine the types of cells expressing these factors in these tissues and to demonstrate the expression of the osteoclastic markers, RANK and tartrate-resistant acid phosphatase (TRAP), in periodontitis. Materials and methods: Frozen biopsy specimens were analysed using specific monoclonal antibodies and were evaluated by semiquantitative analysis and digital image analysis to compare levels of RANKL and OPG protein expression. Double labelling of frozen sections with antibodies to different cell lineage specific markers was used to determine the types of cells expressing these proteins. In situ hybridization was used to detect cells expressing RANK mRNA. Results: Semiquantitative image analysis demonstrated that significantly higher levels of RANKL protein (P < 0.05) were expressed in the periodontitis tissue. Conversely, OPG protein was significantly lower (P < 0.05) in the periodontitis tissues. RANKL protein was associated with lymphocytes and macrophages. OPG protein was associated with endothelial cells in both tissues. Many leukocytes expressing RANK mRNA and TRAP were observed in periodontitis tissues. Conclusion: The change in the levels of these key regulators of osteoclast differentiation may play a major role in the bone loss seen in periodontitis.
引用
收藏
页码:380 / 387
页数:8
相关论文
共 50 条
  • [1] THE EFFECT OF CHLORHEXIDINE ON THE RECEPTOR ACTIVATOR OF NF-κB LIGAND (RANKL) AND OSTEOPROTEGERIN (OPG) EXPRESSION IN CHRONIC PERIODONTITIS IN HUMANS AND COMPANION ANIMALS
    Jankovic, S.
    Aleksic, Z.
    Nikolic, Jakoba Natasa
    Stanimirovic, D.
    Stojic, Z.
    Pucar, Ana
    Hadzi-Mihailovic, M.
    [J]. ACTA VETERINARIA-BEOGRAD, 2010, 60 (5-6): : 641 - 652
  • [2] Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-κB ligand (RANKL) in heterotopic vascular ossification
    Al-Fakhri, N
    Hofbauer, LC
    Preissner, KT
    Franke, FE
    Schoppet, M
    [J]. THROMBOSIS AND HAEMOSTASIS, 2005, 94 (06) : 1335 - 1337
  • [3] Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
    Widschwendter, Martin
    Burnell, Matthew
    Fraser, Lindsay
    Rosenthal, Adam N.
    Philpott, Sue
    Reisel, Daniel
    Dubeau, Louis
    Cline, Mark
    Pan, Yang
    Yi, Ping-Cheng
    Evans, D. Gareth
    Jacobs, Ian J.
    Menon, Usha
    Wood, Charles E.
    Dougall, William C.
    [J]. EBIOMEDICINE, 2015, 2 (10): : 1331 - 1339
  • [4] Expression Profile of Receptor Activator of Nuclear-κB (RANK), RANK Ligand (RANKL) and Osteoprotegerin (OPG) in Breast Cancer
    Owen, Sioned
    Ye, Lin
    Sanders, Andrew J.
    Mason, Malcolm D.
    Jiang, Wen G.
    [J]. ANTICANCER RESEARCH, 2013, 33 (01) : 199 - 206
  • [5] Assessment of receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in lymphoma patients
    Ayoub, M.
    Gadallah, H.
    Hegab, H.
    Khattab, D.
    Mostafa, N.
    [J]. EJC SUPPLEMENTS, 2010, 8 (04): : 22 - 22
  • [6] IDENTIFICATION OF RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-kappa B LIGAND(RANKL) AND OSTEOPROTEGERIN(OPG) IN AMELOBLASTOMA
    Ha, Woo-Hun
    Hwang, Dae-Seok
    Kim, Yong-Deok
    Shin, Sang-Hun
    Kim, Uk-Kyu
    Kim, Jong-Ryoul
    Chung, In-Kyo
    [J]. JOURNAL OF THE KOREAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS, 2007, 33 (02) : 94 - 102
  • [7] Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis
    Grimaud, E
    Soubigou, L
    Couillaud, S
    Coipeau, P
    Moreau, A
    Passuti, N
    Gouin, F
    Redini, F
    Heymann, D
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (05): : 2021 - 2031
  • [8] Glucocorticoid regulation of receptor activator of NF-κB (RANK), osteoprotegerin (OPG) and RANK ligand (RANKL) in mouse calvarial bone.
    Swanson, C
    Lorentzon, M
    Conaway, H
    Lerner, UH
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S200 - S200
  • [9] Osteoprotegerin (OPG) and receptor activator of NF-κB ligand (RANKL) serum levels in short children with and without growth hormone deficiency
    Flint, Janna
    Suarez, Elizabeth
    De Luca, Francesco
    [J]. HORMONE RESEARCH, 2006, 65 : 130 - 130
  • [10] Expression of osteoprotegerin (OPG) and receptor activator of NFkB ligand (RANKL) in 70 breast cancer cells and effects of GnRH treatment on RANKL expression
    Grundker, C.
    Schulz, H.
    Frosch, K. H.
    Emons, G.
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 115 : S44 - S44